Back to Search
Start Over
Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?
- Source :
-
PloS one [PLoS One] 2023 Mar 30; Vol. 18 (3), pp. e0283478. Date of Electronic Publication: 2023 Mar 30 (Print Publication: 2023). - Publication Year :
- 2023
-
Abstract
- Background: Twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may reduce drug adherence compared with once-daily dosing of NOACs in patients with atrial fibrillation (AF), thus worsening clinical outcomes. We evaluated adherence to apixaban and dabigatran requiring twice-daily dosing compared with edoxaban or rivaroxaban with a once-daily dosing regimen and the subsequent clinical outcomes in patients with AF.<br />Methods: Adherence to each NOAC and outcomes were compared between patients who were diagnosed with AF and initiated NOACs between 2016 and 2017 using Korean claims data. High adherence was defined as the proportion of days covered (PDC) of the index NOAC ≥80%. The clinical outcomes included stroke, acute myocardial infarction, death, and composite outcome.<br />Results: A total of 33,515 patients were analyzed (mean follow-up, 1.7 ± 1.3 years). The proportion of patients with high adherence to NOACs was 95%, which did not significantly differ according to the dosing regimen. The mean PDC for NOACs was as high as ~96%, which was the highest for apixaban users, intermediate for edoxaban or rivaroxaban users, and lowest for dabigatran users, regardless of the dosing regimen. Adverse outcomes in low adherence patients for each NOAC were higher than that of high adherence patients, regardless of the dosing frequency.<br />Conclusions: Adherence between once- and twice-daily dosing NOACs in patients with AF was high and similar among both dosing regimens. Patients with low NOAC adherence had poorer clinical outcomes, regardless of the dosing frequency.<br />Competing Interests: None declared.<br /> (Copyright: © 2023 Hwang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Subjects :
- Humans
Anticoagulants
Rivaroxaban therapeutic use
Dabigatran therapeutic use
Administration, Oral
Pyridones therapeutic use
Atrial Fibrillation complications
Atrial Fibrillation drug therapy
Atrial Fibrillation chemically induced
Stroke drug therapy
Stroke etiology
Stroke prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1932-6203
- Volume :
- 18
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- PloS one
- Publication Type :
- Academic Journal
- Accession number :
- 36996134
- Full Text :
- https://doi.org/10.1371/journal.pone.0283478